Properdin homeostasis requires turnover of the alternative complement pathway
暂无分享,去创建一个
[1] M. Pangburn,et al. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. , 2010, Immunobiology.
[2] D. Hourcade,et al. Properdin: emerging roles of a pattern-recognition molecule. , 2010, Annual review of immunology.
[3] T. Hughes,et al. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. , 2009, Molecular immunology.
[4] L. Trouw,et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation , 2008 .
[5] J. Atkinson,et al. Membrane Protein Crry Maintains Homeostasis of the Complement System1 , 2008, The Journal of Immunology.
[6] D. Hourcade,et al. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis , 2008, Proceedings of the National Academy of Sciences.
[7] T. Miwa,et al. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. , 2008, Blood.
[8] D. Hourcade,et al. Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.
[9] K. Yudoh,et al. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. , 2007, Arthritis and rheumatism.
[10] J. Atkinson,et al. Targeted and restricted complement activation on acrosome-reacted spermatozoa. , 2005, The Journal of clinical investigation.
[11] D. Nelson,et al. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. , 2003, Immunity.
[12] M. Walport,et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.
[13] J. Volanakis,et al. Complement activation in factor D-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Zabner,et al. Expression of the Complement Anaphylatoxin C3a and C5a Receptors on Bronchial Epithelial and Smooth Muscle Cells in Models of Sepsis and Asthma1 , 2001, The Journal of Immunology.
[15] yang-xin fu,et al. Impaired Affinity Maturation in Cr2−/− Mice Is Rescued by Adjuvants Without Improvement in Germinal Center Development1 , 2000, The Journal of Immunology.
[16] B. Palanca,et al. A critical role for murine complement regulator crry in fetomaternal tolerance. , 2000, Science.
[17] H. Colten,et al. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. , 1999, Immunopharmacology.
[18] John D Lambris,et al. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] Pier Paolo Pandolfi,et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.
[20] H. Colten,et al. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. Dewald,et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. , 1997, Journal of immunology.
[22] R. Karr,et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] P. Butko,et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. H. Jansen,et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. , 1995, The Journal of clinical investigation.
[25] D. Hourcade,et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein , 1995, The Journal of experimental medicine.
[26] H. Ziegler-Heitbrock,et al. Expression of properdin in human monocytes. , 1994, European journal of biochemistry.
[27] W. Dippold,et al. Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. , 1993, Journal of immunology.
[28] H. Müller-Eberhard,et al. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. , 1989, Molecular immunology.
[29] Y. Boyd,et al. Localization of the properdin structural locus to Xp11.23-Xp21.1. , 1989, Genomics.
[30] T. Farries,et al. Biosynthesis of properdin. , 1989, Journal of immunology.
[31] C. López-Larrea,et al. A familial deficiency of complement factor H , 1987 .
[32] M. Gubler,et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. , 1986, Kidney international.
[33] D. Fearon,et al. p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. , 1985, Journal of immunology.
[34] R. Thompson,et al. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. , 1981, Clinical and experimental immunology.
[35] J. Atkinson,et al. Reduced concentrations of the first component of complement in hypogammaglobulinemia: Correction by infusion of γ-globulin , 1978 .
[36] D. Fearon,et al. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase , 1975, The Journal of experimental medicine.
[37] J. Ziegler,et al. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. , 1975, The Journal of clinical investigation.
[38] H. Müller-Eberhard,et al. Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. , 1972, The Journal of clinical investigation.
[39] F. Rosen,et al. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. , 1970, The Journal of clinical investigation.
[40] H. J. Muller-Eberhard,et al. Complement-Immunoglobulin Relation: Deficiency of C'lq Associated with Impaired Immunoglobulin G Synthesis , 1969, Science.
[41] A. Wardlaw,et al. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. , 1954, Science.
[42] P. Lachmann. The amplification loop of the complement pathways. , 2009, Advances in immunology.
[43] John D Lambris,et al. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. , 2007, Molecular immunology.
[44] J. V. van Strijp,et al. Anaphylatoxins: their role in bacterial infection and inflammation. , 2007, Immunologic research.
[45] David Garrick,et al. Repeat-induced gene silencing in mammals , 1998, Nature Genetics.
[46] J. Atkinson,et al. Control of the complement system. , 1996, Advances in immunology.
[47] H. Müller-Eberhard,et al. Molecular organization and function of the complement system. , 1988, Annual review of biochemistry.
[48] J. Atkinson,et al. Reduced concentrations of the first component of complement in hypotammaglobulinemia: correction of infusion of gamma-globulin. , 1978, Clinical immunology and immunopathology.
[49] Louis Pillemer,et al. THE PROPERDIN SYSTEM AND IMMUNITY III. THE ZYMOSAN ASSAY OF PROPERDIN , 1956 .